Journal
NATURE IMMUNOLOGY
Volume 19, Issue 3, Pages 222-232Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41590-018-0044-z
Keywords
-
Categories
Funding
- Else-Kroner-Stiftung
- Deutsche Forschungsgemeinschaft [5892/5-1]
- European Research Council (consolidator grant HepatoMetaboPath)
- European Research Council [SFBTR36, SFBTR179, SFBTR209]
- European Research Council (European Union's Horizon research and innovation programme) [667273]
Ask authors/readers for more resources
In contrast to most other malignancies, hepatocellular carcinoma (HCC), which accounts for approximately 90% of primary liver cancers, arises almost exclusively in the setting of chronic inflammation. Irrespective of etiology, a typical sequence of chronic necroinflammation, compensatory liver regeneration, induction of liver fibrosis and subsequent cirrhosis often precedes hepatocarcinogenesis. The liver is a central immunomodulator that ensures organ and systemic protection while maintaining immunotolerance. Deregulation of this tightly controlled liver immunological network is a hallmark of chronic liver disease and HCC. Notably, immunotherapies have raised hope for the successful treatment of advanced HCC. Here we summarize the roles of specific immune cell subsets in chronic liver disease, with a focus on non-alcoholic steatohepatitis and HCC. We review new advances in immunotherapeutic approaches for the treatment of HCC and discuss the challenges posed by the immunotolerant hepatic environment and the dual roles of adaptive and innate immune cells in HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available